Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK

OBJECTIVES: Tiotropium (TIO), Spiriva® Handihaler®, is a well-established bronchodilator, LAMA (long acting muscarinic antagonist), for the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD). Clinical evidence from the SPARK trial suggests that TIO is superior to glyco...

Descripción completa

Detalles Bibliográficos
Autores principales: Eklund, Oskar, Afzal, Faraz, Borgström, Fredrik, Flavin, Jason, Ternouth, Andrew, Ojanguren, Maria Eugenia, Crespo, Carlos, Baldwin, Mike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910617/
https://www.ncbi.nlm.nih.gov/pubmed/27354818
http://dx.doi.org/10.2147/CEOR.S105579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910617/
https://www.ncbi.nlm.nih.gov/pubmed/27354818
http://dx.doi.org/10.2147/CEOR.S105579

Ejemplares similares